Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling

Significance Target selection for the development of antibody-directed therapies is commonly driven by a specific hypothesis or based on expression profile analysis, which require laborious experimental validation. We developed a pooled screening platform for the unbiased, high-throughput identification of multiple cancer-specific targets in a single screen. Applying this technology resulted in the identification of multiple therapeutic target candidates in ovarian cancer. In addition to the selection of cell type-specific targets, the platform simultaneously allows the discovery of antibodies with therapeutic potential, thereby bypassing the need for lengthy antibody discovery campaigns.

[1]  Copyright 2022 , 2022, 2022 19th International SoC Design Conference (ISOCC).

[2]  E. Engleman,et al.  Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.

[3]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[4]  Xiaoqiang Si,et al.  CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[6]  A. D. de Brevern,et al.  Dimerization and phosphorylation of Lutheran/basal cell adhesion molecule are critical for its function in cell migration on laminin , 2019, The Journal of Biological Chemistry.

[7]  Li Liu,et al.  Lost expression of cell adhesion molecule 1 is associated with bladder cancer progression and recurrence and its overexpression inhibited tumor cell malignant behaviors , 2018, Oncology letters.

[8]  Mathias Wilhelm,et al.  A deep proteome and transcriptome abundance atlas of 29 healthy human tissues , 2018, bioRxiv.

[9]  Y. Negishi,et al.  Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates , 2018, Scientific Reports.

[10]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[12]  Jennifer J. Hill,et al.  Biotin-transfer from a trifunctional crosslinker for identification of cell surface receptors of soluble protein ligands , 2017, Scientific Reports.

[13]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[14]  R. Aebersold,et al.  On the Dependency of Cellular Protein Levels on mRNA Abundance , 2016, Cell.

[15]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[16]  A. Milosavljevic,et al.  Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma , 2015, Proceedings of the National Academy of Sciences.

[17]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[18]  C. Meijer,et al.  CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer , 2014, Journal of Clinical Pathology.

[19]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[20]  M. Nomizu,et al.  The Lutheran/Basal Cell Adhesion Molecule Promotes Tumor Cell Migration by Modulating Integrin-mediated Cell Attachment to Laminin-511 Protein* , 2013, The Journal of Biological Chemistry.

[21]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[22]  Zhengwei Zhu,et al.  CD-HIT: accelerated for clustering the next-generation sequencing data , 2012, Bioinform..

[23]  F. Claret,et al.  Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer , 2012, Front. Oncol..

[24]  H. Tsuda,et al.  Expression of a splicing variant of the CADM1 specific to small cell lung cancer , 2012, Cancer science.

[25]  A. Rust,et al.  Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1 , 2012, Molecular Cancer.

[26]  D. Harrison,et al.  Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer , 2012, British Journal of Cancer.

[27]  Xiaomei Li,et al.  TSLC1 gene silencing in cutaneous melanoma , 2010, Melanoma research.

[28]  J. Berkhof,et al.  Association between dense CADM1 promoter methylation and reduced protein expression in high‐grade CIN and cervical SCC , 2008, The Journal of pathology.

[29]  N. Burton,et al.  Molecular structure of the extracellular region of Lutheran blood group glycoprotein and location of the laminin binding site. , 2008, Blood cells, molecules & diseases.

[30]  C. L. Oliveira,et al.  The Laminin 511/521-binding site on the Lutheran blood group glycoprotein is located at the flexible junction of Ig domains 2 and 3. , 2007, Blood.

[31]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Adam Godzik,et al.  Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences , 2006, Bioinform..

[33]  M. Telen,et al.  The Lutheran glycoprotein: a multifunctional adhesion receptor , 2006, Transfusion.

[34]  Y. Kikkawa,et al.  Review: Lutheran/B-CAM: A Laminin Receptor on Red Blood Cells and in Various Tissues , 2005, Connective tissue research.

[35]  Yoshinori Murakami,et al.  Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. , 2004, Blood.

[36]  H. Fukuhara,et al.  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines , 2003, International journal of cancer.

[37]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Sakai,et al.  HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab , 2002, Japanese journal of cancer research : Gann.

[39]  S. Gygi,et al.  Proteomics: the move to mixtures. , 2001, Journal of mass spectrometry : JMS.

[40]  Gérard Lefranc,et al.  The Immunoglobulin FactsBook , 2001 .

[41]  S. Barth,et al.  Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages. , 2001, BioTechniques.

[42]  G. Fleuren,et al.  The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. , 1998, British Journal of Cancer.

[43]  P. Gane,et al.  The Lutheran Blood Group Glycoproteins, the Erythroid Receptors for Laminin, Are Adhesion Molecules* , 1998, The Journal of Biological Chemistry.

[44]  G. Truskey,et al.  Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. , 1998, The Journal of clinical investigation.

[45]  A. Barclay,et al.  The Lutheran blood group glycoprotein, another member of the immunoglobulin superfamily, is widely expressed in human tissues and is developmentally regulated in human liver. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Haynes,et al.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.

[47]  I. Campbell,et al.  Non-polarized expression of Basal-cell adhesion molecule B-cam in epithelial ovarian cancers. , 1994, International journal of oncology.

[48]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[49]  J. Johnson,et al.  The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family , 1993, Melanoma research.

[50]  D. Bachir,et al.  Aggregation of mononuclear and red blood cells through an alpha4beta1-Lu/basal cell adhesion molecule interaction in sickle cell disease , 2019 .

[51]  J. Thigpen.  Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer , 2011 .

[52]  S. Salzberg,et al.  FLASH: fast length adjustment of short reads to improve genome assemblies , 2011, Bioinform..

[53]  G. Daniels,et al.  Use of domain-deletion mutants to locate Lutheran blood group antigens to each of the five immunoglobulin superfamily domains of the Lutheran glycoprotein: elucidation of the molecular basis of the Lu(a)/Lu(b) and the Au(a)/Au(b) polymorphisms. , 1997, Blood.